Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer.
Tenascin-C (TNC), as a member of the extracellular matrix (ECM), plays an important role in cancer cell proliferation and migration and tumor invasion in various types of cancer. Here, we attempted to investigate the role of TNC as a prognostic factor in prostate cancer. We studied TNC expression via immunohistochemistry in 145 prostate cancer tissue samples. The clinicopathological relevance of TNC expression was examined, as well as other cancer-associated fibroblasts (CAFs)-related factors. Our results showed that the high levels of TNC expression in prostate cancer stroma was significantly associated with lymph node metastasis (P = 0.024) and clinical stage (P = 0.032). Furthermore, TNC was positively correlated with increased micro-vessel density (MVD) (P = 0.017) and tumor associated macrophage (TAM) population (P = 0.025). In both univariate and multivariate Cox regression analyses, TNC (P < 0.001) was an independent poor prognostic factor for overall survival in prostate cancer patients. Moreover, over-expression of TNC (P < 0.001), SMA (P = 0.042) and vimentin (P = 0.010) were significantly correlated with the lower overall survival. In addition, TNC expression in prostate cancer stroma was significantly associated with FSP1 (P = 0.011), SMA (P = 0.021), and vimentin (P = 0.002). In conclusion, our study revealed that high level of TNC as a potential biomarker of CAFs was significantly correlated with the poor prognosis for prostate cancer patients.
Key Laboratory of Natural Resources of the Changbai Mountain and Functional Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji 133002, China.
Wei-Dong
WD
Ni
Key Laboratory of Natural Resources of the Changbai Mountain and Functional Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji 133002, China.
Zhao-Ting
ZT
Yang
Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji 133002, China.
Chun-Ai
CA
Cui
Department of Oncology, Affiliated Hospital of Yanbian University, Yanji 133002, China.
Yan
Y
Cui
Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji 133002, China; Department of Surgery, Affiliated Hospital of Yanbian University, Yanji 133002, China. Electronic address: flying036@163.com.
Long-Yun
LY
Fang
Key Laboratory of Natural Resources of the Changbai Mountain and Functional Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; Institute for Regenerative Medicine, Yanbian University College of Medicine, Yanji 133002, China. Electronic address: xuanyh1@ybu.edu.cn.
Yan-Hua
YH
Xuan
D000199:Actins / Q000235:genetics* / Q000378:metabolism; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000235:genetics / Q000378:metabolism; D000072645:Cancer-Associated Fibroblasts / Q000378:metabolism / Q000473:pathology; D002277:Carcinoma / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D000071999:S100 Calcium-Binding Protein A4; D015398:Signal Transduction; D016019:Survival Analysis; D019063:Tenascin / Q000235:genetics* / Q000378:metabolism; D014746:Vimentin / Q000235:genetics* / Q000378:metabolism
C541116:ACTA2 protein, human; D000199:Actins; D014408:Biomarkers, Tumor; D002135:Calcium-Binding Proteins; D000071999:S100 Calcium-Binding Protein A4; D019063:Tenascin; D014746:Vimentin; C077591:S100A4 protein, human
Cancer-associated fibroblasts; Prognosis; Prostate cancer; Tenascin-C